excessive daytime sleepiness eds epidemiology forecast

Overview

DelveInsight’s Excessive Daytime Sleepiness - Epidemiology Forecast–2034’ report delivers an in-depth understanding of the excessive daytime sleepiness, historical and forecasted epidemiology as well as the excessive daytime sleepiness trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan. 

Excessive Daytime Sleepiness Disease Understanding

Excessive Daytime Sleepiness is characterized by difficulty in staying awake and alert during the major waking episodes of the day, with sleep occurring unintentionally or at inappropriate times of the wake period. Excessive Daytime Sleepiness is often associated with a wide range of illnesses, including metabolic, cardiovascular, neurological, and psychiatric diseases with voluntary behaviors reflecting poor sleep and sleep debt, leading to disability and increased risk of mortality. Excessive Daytime Sleepiness is also commonly associated with social and economic consequences, thus constituting a significant public health problem.

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Sleep plays a vital role in consolidating memory, restoring the immune system, and other vital processes. As a result, a lack of quality sleep may result in a host of symptoms that may not immediately connect to the sleep.

Excessive Daytime Sleepiness Diagnosis 

If an individual constantly feels drowsy during the day and tends to fall asleep at an awkward time and places that affect the productivity of the individual, then that individual needs to consult with a treating physician and discuss the situation. The physician will inquire about the sleeping habits of the patient. The physician will also inquire about any history of alcohol or drug use or abuse currently or in the past. The individual may also be referred to a psychologist for a counseling session if the individual has some stress or emotional problem in life, which could be interfering with sleep. The physician may also order tests to know about the exact cause of Excessive Daytime Sleepiness.

Sleep studies, such as the polysomnogram (PSG), the multiple sleep latency tests (MSLT), and the maintenance of wakefulness test (MWT), must be performed in a sleep laboratory, and although more labor-intensive, may also help evaluate diminished alertness and excessive sleepiness.

Continued in the report…..

Excessive Daytime Sleepiness Epidemiology Perspective by DelveInsight

Excessive Daytime Sleepiness, best described as an urge to sleep during daytime hours, is a common problem, occurring at least 3 days a week in ~4–20% of the population. It affects the quality of life, workplace productivity, and performance, and has safety implications, specifically, while driving. Excessive daytime sleepiness is associated with sleep disorders that are often underdiagnosed and misdiagnosed. For the epidemiology model, five conditions, which include Parkinson’s disease, Narcolepsy, Obstructive Sleep Apnea (OSA), Idiopathic Hypersomnia (IH), and Bipolar Disorder, have been considered, to estimate the cases of excessive daytime sleepiness.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the total diagnosed prevalent cases of excessive daytime sleepiness, and total diagnosed prevalent cases of excessive daytime sleepiness in different disorders, in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2021 to 2034.

Excessive Daytime Sleepiness Detailed Epidemiology Segmentation

• Total diagnosed prevalent cases of Excessive Daytime Sleepiness in the 7MM were found to be around 7 million cases in 2023, which are expected to increase during the study period (2021-2034), due to a rise in the prevalence of associated conditions.
• According to DelveInsight estimates, in 2023, the diagnosed prevalent cases of Excessive Daytime Sleepiness in the United States were estimated to be around 3.9 million, and these are projected to rise by 2034, with increased focus on improving disease awareness, improved differential diagnosis from conditions like fatigue, and a rise in awareness of lifestyle and mental health conditions like stress and depression.
• There were around 2 million total diagnosed prevalent cases of Excessive Daytime Sleepiness, in EU4 and the UK, in 2023. Among these, Germany had the highest diagnosed prevalent cases, followed by France. Though Excessive Daytime Sleepiness is a common issue in Europe, affecting a significant proportion of individuals and potentially impacting their daily functioning and quality of life, there was a scarcity of data for disease diagnosis, and associated conditions like OSA, or high misdiagnosis for conditions like bipolar.
• Among the various conditions associated with excessive daytime sleepiness, in 2023 in the US, there were approximately the highest cases of excessive daytime sleepiness, nearly 2 million were diagnosed with OSA, followed by bipolar disorder with about 1 million cases, and approximately 611 thousand cases of Parkinson’s disease. 
• It was observed that Japan accounted for approximately 16% diagnosed prevalent population of Excessive Daytime Sleepiness, among 7MM, in the year 2023. There is high misdiagnosis as often the symptoms are non-specific. The lack of understanding of the clinical course and clinical relevance, further adds to difficulties in assessing disease prevalence. 

Scope of the Report

• The report covers a descriptive overview of Excessive Daytime Sleepiness, explaining its signs and symptoms, causes, and classification.
• The report provides insight into the 7MM historical and forecasted patient population covering the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• The report assesses the disease risk and burden of Excessive Daytime Sleepiness.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM, total diagnosed prevalent cases of excessive daytime sleepiness, and total diagnosed prevalent cases of excessive daytime sleepiness in different disorders.

Report Highlights

• 10-year forecast of Excessive Daytime Sleepiness
• The 7MM Coverage 
• Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness
• Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders

Key Questions Answered

• What are the disease risks and burdens of Excessive Daytime Sleepiness?
• What is the historical Excessive Daytime Sleepiness patient population in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• What would be the forecasted patient population of Excessive Daytime Sleepiness at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population of Excessive Daytime Sleepiness?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Excessive Daytime Sleepiness during the forecast period (2024–2034)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2024–2034)?

Reasons to buy

The Excessive Daytime Sleepiness report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM Excessive Daytime Sleepiness epidemiology forecast.
• The Excessive Daytime Sleepiness epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Excessive Daytime Sleepiness epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Risk of disease by the segmentation 
• Factors driving growth in a specific patient population